Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 09:22 ET | Source: Spherix Global Insights

Emerging Treatments Drive Notable Changes in IgA Nephropathy Care Across Key Global Markets, According to Spherix Global Insights

EXTON, PA, May 08, 2025 (GLOBE NEWSWIRE) -- With multiple targeted therapies now available and SGLT2 inhibitors broadly embraced, nephrologists across the globe are redefining how they manage IgA...
April 08, 2025 10:53 ET | Source: Spherix Global Insights

Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights

EXTON, PA, April 08, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at the...
April 02, 2025 05:00 ET | Source: Averoa

AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)

CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemiaFinal European Commission decision...
March 26, 2025 13:35 ET | Source: Spherix Global Insights

Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights

EXTON, PA, March 26, 2025 (GLOBE NEWSWIRE) -- Nearly all nephrologists agree that early and aggressive intervention is essential for improving outcomes in IgA nephropathy (IgAN). However, findings...
February 19, 2025 10:14 ET | Source: Spherix Global Insights

Spherix Global Insights and the American Kidney Fund Announce Strategic Partnership and Inaugural Initiative to Elevate the Voice of Kidney Patients – Beginning with IgAN Patients

EXTON, PA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights is proud to announce its partnership with the American Kidney Fund (AKF), marking a significant milestone in a collaboration...
February 05, 2025 09:33 ET | Source: Spherix Global Insights

Amid Novo Nordisk’s Win for Ozempic’s Expanded Label to Include Chronic Kidney Disease Benefits, Spherix Global Insights Highlights Nephrologists’ Rising Influence in GLP-1 RA Utilization

EXTON, PA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- As chronic kidney disease (CKD) management evolves, new findings from Spherix Global Insights’ annual Patient Chart Dynamix™: CKD Non-Dialysis...
November 15, 2024 13:15 ET | Source: Spherix Global Insights

Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission

EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G often...
November 01, 2024 09:17 ET | Source: Spherix Global Insights

Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs

EXTON, PA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Focal segmental glomerulosclerosis (FSGS), one of the most common glomerular diseases seen by nephrologists, ranks among the top three rare kidney...
October 14, 2024 07:03 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

LOS ALTOS, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
October 09, 2024 07:03 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

LOS ALTOS, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...

Next Page keyboard_arrow_right